AlphAIAlphAI — Financial news for AI agents
stocktitan.netAUG 271 min read$AMRN

Amarin (NASDAQ: AMRN) sees Sarissa report 25.7M+ shares

Amarin (AMRN) received an updated filing from Sarissa Capital, showing ownership of 25.7M shares, or 6.09% of outstanding shares. The filing includes recent transactions and shared voting power. The data is based on Amarin's Q2 2026 report.

Original reporting
stocktitan.net
Published Aug 27, 2026, 10:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 9:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$AMRN
Neutral
medium confidence
Mentioned
$AMRN
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$AMRNNeutralLow
01

Why it matters

The filing introduces new ownership data that could influence investor sentiment toward Amarin.

02

Market read

Provides fresh 13D data, modest relevance for Amarin's stock.

03

What to watch

Potential upcoming shareholder proposals or board changes driven by Sarissa.

Relevance 6/10Novelty 7/10Timing: just filed amendment

Background

Amarin filed Amendment No.16 to a Schedule 13D showing Sarissa Capital's 6.09% ownership.

Company-level read

Ticker impact

$AMRNNeutralMedium confidence
Context

Sarissa Capital disclosed beneficial ownership of ~6.09% (25.7M shares) in Amendment No.16 Schedule 13D filing.

Expected impact

Potential modest upside if investors view stake as support, but limited immediate price move.

Evidence & confidence

25.7M shares represent 6% of float; size is notable but not large enough for a sharp move.

Market effects

Sector

May increase scrutiny of biotech ownership disclosures and activist activity.

Regional

US biotech investors may reassess exposure to Amarin.

Global

Limited, primarily affects Amarin and similar small‑cap biotech stocks.

Counterpoint

What could challenge this read

Stake increase may not translate to price gain if investors view it as a passive investment.

Key entities

  • Company
    Amarin Corp PLC

    US‑listed biotech

  • Investment Firm
    Sarissa Capital Management LP

    Beneficial owner of 6% of AMRN

  • Individual
    Alexander J. Denner

    Partner at Sarissa Capital

Read at source← All news

Related articles

OCT 25
$AMRNMedAI 8/10

Amarin’s icosapent ethyl shows survival benefit in cancer trial

Amarin Corporation (NASDAQ:AMRN) reported Phase 3 trial results for icosapent ethyl in colorectal cancer liver metastases. The primary endpoint of progression-free survival was not met, but the key secondary endpoint of overall survival showed a statistically significant benefit. The five-year overall survival estimate was 62.0% with icosapent ethyl versus 45.1% with placebo. The drug was found to be safe and well tolerated.

investing.com2 min
OCT 25
$AMRNMedAI 8/10

A colorectal cancer trial missed its goal, but estimated 5-year survival was 62% with the drug versus 45% with placebo.

Amarin's drug VASCEPA failed to meet its primary endpoint in a colorectal cancer trial but showed a 5-year survival rate of 62% vs. 45% with placebo. The study, sponsored by the University of Leeds, found improved overall survival but not progression-free survival. Amarin plans further evaluation, citing potential long-term value.

stocktitan.net2 min
AUG 8
$AMRNMed

Amarin (AMRN) Q2 2026 Earnings Call Transcript

Amarin (AMRN) reported Q2 2026 results on an earnings call. Total net revenue was $42.2M, down 42% year over year, mainly due to a $25M upfront licensing payment in 2025. U.S. product revenue fell to $32.2M, while Europe product revenue rose to $5.4M. Operating loss narrowed to $12.0M and cash and investments were $314.6M.

fool.com7 min
JUL 29
$AMRNMed

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading…

AMARIN CORP PLC\UK (AMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash

SEC EDGAR 8-K6 min